FGFR2 and breast carcinoma: In breast cancers with FGFR2amp, TP53 driver mutations, MYC amplifications, PTEN loss-of-function alterations, and CCND1 and FGF3/4/19 co-amplifications were significantly more enriched compared with the other classes of FGFR2 aberration (Fig. 3a,b).